OMEROS CORP (OMER) earnings date
Mar 29, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 45 days, typically, give or take 21 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 16, 2026 | after close | 47 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | after close | 43 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | after close | 43 | 8-K |
| Q4 FY2025 | Tue, Mar 31, 2026 | after close | 90 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | after close | 44 | 8-K |
| Q2 FY2025 | Thu, Aug 14, 2025 | after close | 45 | 8-K |
| Q1 FY2025 | Thu, May 15, 2025 | after close | 45 | 8-K |
| Q4 FY2024 | Mon, Mar 31, 2025 | after close | 90 | 8-K |
What they guided beta
| Q3 FY2026 | "Together with expected zaltenibart-related milestone payments from Novo, these revenues are driving the rest of our pipeline forward: the OMS527 Phase 2 trial in cocaine use disorder planned to start early next year; the OncotoX-AML Phase 1b trial slated for late 2027; T-CAT, now in IND-enabling studies; and oral MASP-2 and MASP-3 inhibitors advancing toward the clinic." exhibit |
| Q3 FY2026 | "We continue to provide transition services at Novo’s cost and expect to complete those services by mid-2027." exhibit |
| Q3 FY2026 | "We expect to begin enrollment in the first quarter of 2027." exhibit |
| Q2 FY2026 | "By year-end 2026, we expect enrollment to begin in two investigator-sponsored and Omeros-supported studies, one evaluating YARTEMLEA in hyperinflammatory ARDS, and the other assessing prophylactic YARTEMLEA in pediatric patients with predictably severe TA-TMA." exhibit |
| Q2 FY2026 | "We expect to be able start enrollment in the inpatient clinical trial by year-end 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/OMER
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/OMER
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/OMER/"><img src="https://veritasdata.dev/embed/OMER.svg" alt="OMER earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/OMER/)
Script
<script async src="https://veritasdata.dev/embed/OMER.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/OMER"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.